Crisaborole cream for mild to moderate eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new cream called crisaborole to see if it helps with mild to moderate eczema. You would apply the cream twice a day for four weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 50 years old.
- You have mild to moderate eczema (a doctor will confirm this).
- You can apply the cream twice a day for four weeks.
- You are not pregnant or breastfeeding.
- You have not used certain strong medications (like steroids or antibiotics) in the last two weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two creams for treating mild to moderate eczema in children: crisaborole 2% and tacrolimus 0.1%. It aims to see which one is more effective and safe for your child.
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
This study compares two prescription creams used to treat mild to moderate eczema (atopic dermatitis) in people aged 2 and older. The goal is to see which cream is safer and works better for reducing symptoms like itching and redness.
This study tests two different prescription creams, crisaborole and tacrolimus, to see which works better for treating eczema (also called atopic dermatitis) in people aged 5 to 25. If you or your child have mild to moderate eczema, this trial may help find a more effective treatment option.
This study compares two prescription creams, tacrolimus and crisaborole, to see which works better and is safer for treating mild to moderate eczema over 8 weeks. Both creams are applied to the skin and are alternatives to steroids.
This study tests a new cream (CMS-D001) for people with moderate to severe eczema. Participants will receive either the study cream or a placebo (a cream with no active ingredient) to see if it helps reduce symptoms like itching and redness.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.